What is Minimal Residual Disease (MRD) Negativity?

ASH 2019 – Multiple Myeloma
Videos
Leslie Lauersdorf, ARNP
Moffitt Cancer Center
Tampa Bay, FL
Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients.

Related Items

LCAR-B38M CAR-T Therapy Yields High Complete Response Rate and Survival Time
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
GRIFFIN Study: Daratumumab Deepens Responses Over Time
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Benefit Shown for Daratumumab plus Carfilzomib + Dexamethasone
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Study Moves CAR-T Therapy Forward in Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
In Routine Practice, Ixazomib Regimen Mirrors Efficacy of Clinical Trial
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Multiple Myeloma as a Chronic Disease
By Leslie Lauersdorf, ARNP
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
In Relapsed or Refractory Myeloma, Addition of Elotuzumab to Lenalidomide + Dexamethasone Improves Outcomes with No Detriment to Quality of Life
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications


© Amplity, Inc. All Rights Reserved. Privacy Policy